Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.50 |
| ▸ | DRD2 | P14416 | 6/20 | 0.50 |
| ▸ | HTR7 | P34969 | 6/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312441 | 0.96 | CHRM4 (0.47) | CHRM4DRD2HTR7ACHEBRD4 | |
| SCHEMBL8307649 | 0.91 | CHRM4 (0.49) | CHRM4DRD2HTR7ACHEBRD4 | |
| SCHEMBL30290988 | 0.80 | IDO1 (0.58) | CHRM4DRD2HTR7IDO1 | |
| SCHEMBL4455923 | 0.80 | IDO1 (0.58) | CHRM4DRD2HTR7IDO1 | |
| SCHEMBL6987694 | 0.79 | MTNR1A (0.52) | CHRM4DRD2HTR7 | |
| SCHEMBL8308233 | 0.78 | CHRM4 (0.47) | CHRM4DRD2HTR7 | |
| SCHEMBL12070481 | 0.75 | CHRM4 (0.44) | CHRM4DRD2HTR7IDO1 | |
| SCHEMBL3817898 | 0.74 | ESR1 (0.49) | CHRM4DRD2HTR7 | |
| SCHEMBL3823105 | 0.74 | ESR1 (0.49) | CHRM4DRD2HTR7 | |
| SCHEMBL10823071 | 0.74 | ESR1 (0.49) | CHRM4DRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004087124-A1 | COMPOUNDS HAVING SEROTONIN 5-HT17 RECEPTOR ANTAGONIST ACTIVITY AND MUSCARINIC M4 RECEPTOR AGONIST ACTIVITY AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-14 | — | — | WO | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | CHRM4 794/4885DRD2 1606/4885HTR7 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.